Onartuzumab in lung cancer: the fall of Icarus?
- PMID: 25818471
- DOI: 10.1586/14737140.2015.1031219
Onartuzumab in lung cancer: the fall of Icarus?
Abstract
The development of targeted therapies has led to a revolution in non-small-cell lung cancer, and opened up possibilities for improved personalized medicine. With the constant findings of new targets, a lot of inhibitors are being developed. However, reliable biomarkers are urgently needed. The design of clinical trials needs to become more flexible in order to obtain the best results and gain the US FDA/EMEA approval for the new drugs. A recent example of a failed trial is the Phase III MetLung trial that compared the effects of the c-MET monovalent antibody onartuzumab with erlotinib versus erlotinib alone in late-stage non-small-cell lung cancer. Here, we discuss several points as to why this trial could have failed.
Keywords: Phase I; c-MET; non-small-cell lung cancer; ornatuzumab; trial design.
Similar articles
-
Onartuzumab ineffective in non-small-cell lung cancer.Lancet Oncol. 2017 Feb;18(2):e66. doi: 10.1016/S1470-2045(16)30680-5. Epub 2016 Dec 23. Lancet Oncol. 2017. PMID: 28017663 No abstract available.
-
Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.AAPS J. 2017 Mar;19(2):527-533. doi: 10.1208/s12248-016-0029-5. Epub 2016 Dec 27. AAPS J. 2017. PMID: 28028730 Clinical Trial.
-
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):17-22. Oncology (Williston Park). 2003. PMID: 14682119 Review.
-
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.Clin Lung Cancer. 2012 Nov;13(6):500-4. doi: 10.1016/j.cllc.2012.05.009. Clin Lung Cancer. 2012. PMID: 23063071 Clinical Trial.
-
[THE CURRENT APPROACH TO ADVANCED LUNG CANCER].Harefuah. 2015 Aug;154(8):521-4, 539-40. Harefuah. 2015. PMID: 26480619 Review. Hebrew.
Cited by
-
PET Imaging of Receptor Tyrosine Kinases in Cancer.Mol Cancer Ther. 2018 Aug;17(8):1625-1636. doi: 10.1158/1535-7163.MCT-18-0087. Mol Cancer Ther. 2018. PMID: 30068751 Free PMC article. Review.
-
Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.MAbs. 2017 Nov/Dec;9(8):1262-1269. doi: 10.1080/19420862.2017.1305529. MAbs. 2017. PMID: 29035637 Free PMC article.
-
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.Drugs. 2021 Apr;81(5):547-554. doi: 10.1007/s40265-021-01477-2. Epub 2021 Feb 27. Drugs. 2021. PMID: 33638808 Review.
-
Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes.Clin Cancer Res. 2023 Nov 14;29(22):4549-4554. doi: 10.1158/1078-0432.CCR-23-2222. Clin Cancer Res. 2023. PMID: 37725573 Free PMC article. Review.
-
Effective implementation of novel MET pharmacodynamic assays in translational studies.Ann Transl Med. 2017 Jan;5(1):3. doi: 10.21037/atm.2016.12.78. Ann Transl Med. 2017. PMID: 28164088 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
